QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TWST

QT62Twist Bioscience Corporation
NASDAQ·Healthcare·Medical - Diagnostics & Research·USA
Latest market price
87.56
+4.69+5.66%
OverviewShort InterestFilings
TWSTQT62Twist Bioscience Corporation·NASDAQ
OverviewShort InterestFilings
87.56+5.66%
TA
Loading chart...
Screen all →
TMO+0.63%$464.61DHR-0.33%$177.17IDXX+2.93%$562.09A+2.20%$127.06NTRA+2.19%$231.41IQV-1.70%$167.77ILMN+1.79%$161.93WAT-0.44%$355.44
Snapshot
Index-P/E-EPS (ttm)-1.33
Insider Own4.02%
Shs Outstand62.27M
Perf Week18.24%
Market Cap5.16BForward P/E-EPS next Y-1.36Insider Trans-0.06%Shs Float-Perf Month76.89%
Enterprise Value5.13BPEG-EPS next Q-0.50Inst Own-Short Float-Perf Quarter95.45%
Income-82050720.00P/S12.60EPS this Y-56.06%Inst Trans-Short Ratio-Perf Half Y181.27%
Sales409.48MP/B11.24EPS next Y34.70%ROA-12.02%Short Interest-Perf YTD176.04%
Book/sh7.31P/C-EPS next 5Y-ROE-17.46%52W High88.46 -1.02%Perf Year158.14%
Cash/sh2.76P/FCF-EPS past 3/5Y-ROIC-24.50%52W Low23.30 275.79%Perf 3Y-
Dividend Est.-EV/EBITDA-91.12Sales past 3/5Y22.72% 33.17%Gross Margin52.07%Volatility4.54% 5.09%Perf 5Y-
Dividend TTM-EV/Sales12.54EPS Y/Y TTM43.33%Oper. Margin-33.90%ATR (14)5.07Perf 10Y-
Dividend Ex-Date-Quick Ratio2.42Sales Y/Y TTM30.99%Profit Margin-19.85%RSI (14)74.56Recom2.00
Dividend Gr. 3/5Y-Current Ratio2.70EPS Q/Q6.06%SMA2022.28%Beta2.52Target Price75.00
Payout0.00%Debt/Eq0.21Sales Q/Q19.35%SMA5040.19%Rel Volume2.37Prev Close82.87
Employees923LT Debt/Eq0.26EarningsAug 03SMA200102.74%Avg Volume1.66MPrice87.56
IPO DateOct 31, 2018Option/ShortYes / YesEPS/Sales Surpr.-26.53% 2.78%Net Debt/EBITDA0.48Volume3,938,046Change5.66%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedCowen & Co.Outperform$68 → $89
Jun-15-26InitiatedCanaccordBuy$90
Jun-15-26ReiteratedUBS$89
Jun-11-26ReiteratedPiper SandlerOverweight$85
May-22-26ReiteratedLeerink PartnersOutperform$80
May-05-26ReiteratedRobert W. Baird$50 → $65
May-05-26UpgradeLeerink PartnersMarket Perform → Outperform
May-05-26ReiteratedGuggenheimBuy$50 → $60
Apr-14-26ReiteratedBarclaysOverweight$50 → $55
Feb-03-26ReiteratedRobert W. Baird$33 → $50
Latest News
Jun-18-26
Jun-18-2601:01PM
Twist Bioscience: Huge Downside, With Little Hope Of ProfitsSeekingAlpha
Jun-17-26
Jun-17-2606:33AM
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its CashSeekingAlpha
Jun-15-26
Jun-15-2611:45AM
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $89Benzinga
11:18AM
Canaccord Genuity Initiates Coverage On Twist Bioscience with Buy Rating, Announces Price Target of $90Benzinga
Jun-11-26
Jun-11-2607:11AM
Piper Sandler Initiates Coverage On Twist Bioscience with Overweight Rating, Announces Price Target of $85Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue410377313
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A197186180
Gross Profit213191133
Selling, General and Administrative Excl. Other273247218
Research and Development728091
Other Operating Expense7045
Operating Income-139-136-221
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-59-59-13
Net Income Before Taxes-80-77-208
Income Taxes011
Consolidated Net Income-82-78-209
Net Income From Continuing Operations-82-78-209
Net Income-82-78-209
EPS (Recurring)-1.32-1.30-3.60
EPS (Basic, Before Extraordinaries)-1.32-1.30-3.60
EPS (Diluted)-1.33-1.30-3.60
EBITDA-57-52-177
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio13.244.48—
Gross Margin51.9550.6642.49
Operating Margin-33.90-36.07-70.61
Net Margin-20.00-20.69-66.77
Shares Outstanding626058
Market Capitalization5,4291,688—
Operating Lease Expense
———
Insider Trading Volume
$92.07$82.89$73.70$64.52$55.34● Close Price0.00M2.09M4.17M6.26M8.34MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Green PaulaSVP of Human ResourcesJun 15 '26Option Exercise23.3352,2741,219,552146,842Jun 17 12:00 AM
Green PaulaSVP of Human ResourcesJun 15 '26Sale81.6726,1372,134,488120,705Jun 17 12:00 AM
WERNER ROBERT F.Chief Accounting OfficerJun 08 '26Sale69.201,35994,04646,827Jun 10 12:00 AM
Leproust Emily M.Chief Executive OfficerJun 08 '26Sale69.842,265158,197844,607Jun 10 12:00 AM
Cho DennisSee RemarksJun 08 '26Sale69.8440228,077119,692Jun 10 12:00 AM
Green PaulaSVP of Human ResourcesJun 08 '26Sale69.8488461,742120,705Jun 10 12:00 AM
Cho DennisSee RemarksMay 29 '26Sale69.7514,205990,799120,094Jun 02 12:00 AM
Laponis AdamChief Financial OfficerMay 29 '26Sale70.004,000280,000112,675Jun 02 12:00 AM
Leproust Emily M.Chief Executive OfficerMay 28 '26Sale67.9116,4701,118,555846,872Jun 01 12:00 AM
Leproust Emily M.Chief Executive OfficerMay 28 '26Option Exercise8.8232,940290,530863,342Jun 01 12:00 AM
Starovasnik Melissa A.DirectorMay 28 '26Sale68.002,500170,00022,222Jun 01 12:00 AM
Leproust Emily M.Chief Executive OfficerMay 27 '26Option Exercise8.8250,034441,300871,889May 28 12:00 AM
Leproust Emily M.Chief Executive OfficerMay 27 '26Sale65.2925,0171,633,407846,872May 28 12:00 AM
Starovasnik Melissa A.DirectorMay 26 '26Sale61.0450030,52024,722May 28 12:00 AM
WERNER ROBERT F.Chief Accounting OfficerMay 26 '26Sale62.4880049,98748,186May 28 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR